Huyi Zhang

Characterization of Small-Molecule Drug Substances in Type II DMFs Supporting ANDAs

Part I: Solution Nuclear Magnetic Resonance Spectroscopy

, the authors of "Characterization of Small-Molecule Drug Substances in Type II DMFs Supporting ANDAs, Part I: Solution Nuclear Magnetic Resonance Spectroscopy,” presented the following examples of seven subcategory deficiencies related to solution nuclear magnetic resonance (NMR) in the Type-II drug master files (DMFs):

C NMR spectra without any interpretation.  Please provide a detailed structural elucidation to confirm the structure of drug substance. For 

H NMR, please provide proton numbers, multiplicity, 

 coupling constant if applicable, and assignment to all the signals in a tabular format.

C HMQC spectroscopic data to ambiguously confirm the proposed structure of the drug substance.

H NMR spectrum and data assignment for the drug substance.  However, your assignment on Multiplicity, Integration, and Position of proton are not in agreement with the proposed structure. Please provide 

C HMQC data for the drug substance to verify the elucidation of drug substance.

		There are several issues regarding the 

H NMR elucidation of Impurity-D: (i) the 6-position is a quaternary carbon that has been assigned a proton with a peak of multiplet; (ii) two protons at 5-position: one has been assigned as a doublet (

 = 8.3 Hz) while another was assigned as a singlet; and (iii) the assignment for the proton at 8-positon is missing. Please explain and correct them accordingly.

		Please explain the peak at δ 13.4 ppm on the 

H NMR spectrum of the drug substance, which does not correspond to the proposed structure. Please clarify if the compound is free base or a salt.

C NMR spectra of the drug substance with the 

 Reference Standard including peak assignments, good resolution and expansions of the NMR scans at appropriate chemical shifts. Both individual and overlay presentations are preferred.

		Considering the complexity of the drug substance with eight chiral centers, we recommend you to provide comparison of

 Reference Standard and your in-house drug substance working standard to verify the proposed structure of drug substance. Overlaid spectra are preferred for better visualization.

		You did not assign the proton NMR peaks of working standard and production lot at 10.70, 4.39, 4.38, and ~1.3 ppm.  Please assign these peaks accordingly. In addition, we recommend that you compare 

H NMR of your in-house working standard with that of a 

 Reference Standard. For a better visualization, please provide overlaid spectra of your in-house working standard and the 

	Spectra not matched with reference standards (RS)

 Reference Standard are different in chemical shifts and splitting patterns from the range of 4.0 to 4.5 ppm. Please explain this discrepancy. In order to eliminate concentration effect on spectra resolution, you may consider providing a 

H NMR spectrum of a mixed sample of drug substance and corresponding 

 Reference Standard and your test sample are not comparable since the 

 Reference Standard is a free base while your test sample is a hydrochloride salt. Please provide overlaid 

 Reference Standard and your test sample in the same form.

OD show different chemical shift, splitting pattern and intensity at 1.0-1.8 ppm and 2.6-2.8 ppm, respectively. In order to eliminate the solvent impacts on the spectra, please provide the 

H NMR spectra in the same deturated solvent. For better visualization, please provide overlaid 

 Reference Standard A and in-house working standard B for better visual comparison.

		The characterization data you provided so far are not sufficient to confirm the 

 fused geometry of the drug substance. Please provide additional evidences to unambiguously determine the 

 fused geometry of drug substance A. The evidences may include, but not limited to, vicinal coupling constants

coupling constants, NOE experiment or NOESY/ROESY.

		The API has several chiral centers which are inherited from procured starting material for which no synthetic chemistry and characterization data was provided. Please discuss in detail how the stereochemistry is established for your API. If the characterization refers to the spectroscopic comparison to the 

 Reference Standard, please explain what comparison data supports the stereochemical features.

		We acknowledge that all the chiral centers of the drug substance are from starting material. However, the potential epimerization of C-4 center under basic conditions will raise uncertainty in stereochemistry. To ensure the consistent quality of drug substance, please provide additional spectroscopic evidences, including but not limited to NOE, to unambiguously determine the absolute configuration of C-4 center of drug substance. The same requirement also applies for characterization of your in-house working standards for impurities A, B, D and E.

C NMR, IR, MS and UV spectra to support the structure of R-enantiomer. However, the provided information cannot differentiate R-enantiomer from S-enantiomer. Please provide additional evidences such as comparison of chiral HPLC retention time or specific optical rotation with that of innovator drug if applicable or Mosher ester analysis for confirming the absolute configuration of R-enantiomer.

H NMR of drug substance, the peaks of protons 4, 8, 5, and 7 from d3.10 to 4.5 ppm are too broad to show the splitting patterns. Please provide a well-resolved 

HNMR spectrum with sharp resonances. You may lower analyte concentration, elevate temperature, use a different deuterated solvent, or transform it to a free base to achieve better resolution.  In addition, please provide 

		The proton NMR spectrum you provided does not allow for adequate evaluation of the structure due to the poor resolution and solvent overlap with critical proton peaks. Please consider using other deuterated solvents with unambiguous peak assignment and enlarge the area with clustered signals for evaluation.

		Please provide the batch number of your drug substance for characterization analysis.

		The carbon NMR spectra provided have very low signal to noise ratios. According to your response, the solubility of drug substance in DMSO is about 76 mg/mL, which is sufficient to obtain a good quality of carbon NMR spectra. Please re-run the experiment and provide an explanation for any differences observed between the lots.

C NMR. It should be 100 MHz, ¼ of that of 1H NMR (400 MHz).

H NMR spectrum provided for your molecule is not readable.  Please provide a legible copy.

Articles

Appendix to Characterization of Small-Molecule Drug Substances in Type II DMFs Supporting ANDAs, Part I: Solution Nuclear Magnetic Resonance Spectroscopy

Appendix: Common Deficiencies Related to Solution NMR in the Type-II DMFs

The authors present analysis of the state of control of intermediate identity and quality, based on analysis of recently submitted DMFs.

’s 2016 Solid Dosage Drug Development and Manufacturing eBook.